SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Oberg Kjell) "

Sökning: WFRF:(Oberg Kjell)

  • Resultat 1-50 av 71
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  •  
6.
  • Ekeblad, Sara, et al. (författare)
  • Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution
  • 2008
  • Ingår i: Clinical Cancer Research. - 1078-0432 .- 1557-3265. ; 14:23, s. 7798-7803
  • Tidskriftsartikel (refereegranskat)abstract
    • PURPOSE: Unequivocal pathologic markers for the prognosis of pancreatic endocrine tumors are often lacking. Suggestions for prognostic guidance include the WHO classification. Recently, a tumor-node-metastasis (TNM) staging system was proposed. We evaluate this system, as well as assess other potential prognostic factors such as tumor Ki67, size, endocrine syndrome, heredity, body mass index (BMI), and plasma chromogranin A, in a large patient material treated at a single institution. EXPERIMENTAL DESIGN: A total of 324 patients with pancreatic endocrine tumor, consecutively diagnosed and treated at a tertiary referral center, were retrospectively evaluated. Median follow-up was 54 months (range, 1-423 months). Patient and tumor data were extracted from medical records. Univariate and multivariate analyses were done to recognize factors of prognostic value. RESULTS: The median overall survival was 99 months (95% confidence interval, 81-117). Five- and 10-year survival rates were 64% and 44%, respectively. In univariate analysis, TNM stage, radical surgery, WHO classification, nonfunctioning tumor, Ki67 ≥2%, chromogranin A ≥3 times the upper normal limit, BMI <20 kg/m2, sporadic tumor, tumor size, and referral from our primary uptake area had a significant prognostic effect. In multivariate analysis, TNM stage, WHO classification, radical surgery, and Ki67 ≥2% retained their significance. Having a nonfunctioning tumor was not an independent marker of poor prognosis and neither was heredity. CONCLUSIONS: The recently suggested TNM staging system emerged as a useful clinical tool.
  •  
7.
  •  
8.
  •  
9.
  •  
10.
  •  
11.
  •  
12.
  • Eriksson, Barbro, et al. (författare)
  • Suprarenomas
  • 1995
  • Ingår i: Therapiekonzepte Onkologie/Therapies and Strategies in Oncology 1995, 2nd edition.. - : Springer Verlag.
  • Bokkapitel (övrigt vetenskapligt/konstnärligt)
  •  
13.
  •  
14.
  •  
15.
  •  
16.
  •  
17.
  •  
18.
  •  
19.
  • Granberg, Dan, et al. (författare)
  • Neuroendocrine tumours.
  • 2005
  • Ingår i: Cancer Chemother Biol Response Modif. - 0921-4410. ; 22, s. 471-83
  • Recension (refereegranskat)
  •  
20.
  •  
21.
  •  
22.
  •  
23.
  •  
24.
  •  
25.
  •  
26.
  •  
27.
  •  
28.
  •  
29.
  • Liu, Minghui, 1977- (författare)
  • Gene Therapy with Interferon Alpha and the Angiogenic Inhibitor, Vasostatin, in Neuroendocrine Tumors of the Digestive System
  • 2007
  • Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
    • IFN-α has been applied in medical treatment of various neuroendocrine (NE) tumors, either alone or combination with somatostatin analogues. They can improve clinical symptoms in 50-70% of patients but a significant tumor reduction is only observed in 5-15% patients. Vasostatin (vaso) is believed to be an angiogenic inhibitor. The aim of this study is to evaluate the feasibility to use IFN-α and vasostatin gene therapy in NE tumors. We constructed plasmid vectors carrying human IFN-α2 (hIFN-α2) gene and human vasostatin gene, which were transfected into BON I cell to obtain stable gene-expressing cell lines. We found that in animal tumor model and cell experiments gene transfer of vasostatin caused a faster cell growth and tumor development via down-regulation of the tumor suppressor gene and p27. Cell adhesion, spreading, migration and invasion ability were increased in vaso-expressing BON I cells. Transfecting chicken vinculin could reverse the malignant behavior and restored expression of tumor suppressor genes. Moreover, vinculin knockdown could result in a faster cell growth and an increased colony formation. Condition medium taken from hIFN-α2-expressing BON I cells showed significant antiproliferative effects both on the NE tumor cells, BON I and LCC18, and the endothelial cells, PAE. It also suppressed cell adhesion and cell invasion and inhibited angiogenesis on CAM assay. Mice implanted with a mixture of WT BON cells and hIFN-α2-expressing BON cells (1:1) demonstrated significantly lower tumor incidence and longer tumor doubling time. Furthermore, long-acting IFN-α2b (PEGIntron®) demonstrated a better anti-tumor effect in contrast with IFN-α2b (IntronA®). Intratumoral injection of hIFN-α2 plasmids significantly inhibited NE tumor growth and caused tumor regression. We concluded that gene transfer of vasostatin into BON I cells might cause an enhanced malignant tumor behavior. Therefore, vasostatin therapy can not be recommended for patients with NE tumors. Vinculin might play an important role in NE tumor development and growth regulation. Gene therapy by using plasmid DNA carrying hIFN-α2 gene is feasible and promising in NE tumors.
  •  
30.
  •  
31.
  •  
32.
  •  
33.
  •  
34.
  •  
35.
  • Oberg, K., et al. (författare)
  • Comparison of monolayer films of stearic acid and methyl stearate on an Al2O3 surface
  • 2001
  • Ingår i: Thin Solid Films. - : Elsevier. - 0040-6090. ; 397:1-2, s. 102-8
  • Tidskriftsartikel (refereegranskat)abstract
    • Both stearic acid and methyl stearate chemisorbs onto an oxide surface of aluminum with an asymmetric coordination of the carboxylate group as concluded from infrared (IR) spectroscopy data. Similarities in the IR spectra of the films from the two compounds suggest that the ester is bonded in the same way as the acid, and that the ester therefore undergoes hydrolysis during the surface reaction. X-Ray photoelectron spectroscopy (XPS) and IR data are interpreted in terms of self-assembled monolayer formation and a more dense film from the carboxylic acid in comparison with that from the ester. (C) 2001 Elsevier Science B.V. All rights reserved.
  •  
36.
  • Oberg, Kjell (författare)
  • Ektopiskt ACTH-syndrom
  • 1997
  • Ingår i: Läkartidningen. ; 94, s. 941-
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
37.
  • Oberg, Kjell, et al. (författare)
  • Endocrine tumours of the pancreas.
  • 2005
  • Ingår i: Best Pract Res Clin Gastroenterol. - 1521-6918. ; 19:5, s. 753-81
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
38.
  •  
39.
  •  
40.
  •  
41.
  •  
42.
  •  
43.
  •  
44.
  •  
45.
  •  
46.
  •  
47.
  •  
48.
  •  
49.
  •  
50.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-50 av 71

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy